Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$1.89
EPS est.
$2.77
EPS surprise
-31.77%
1-day move
+1.81%
Bio-Rad Laboratories reported earnings that fell short of expectations on EPS, which typically raises concerns among investors. However, the stock reacted positively, increasing by 1.81%. This could indicate that investors are optimistic about future performance despite the earnings miss, or that the market had already priced in lower expectations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.89 | $1.99 | -5.0% |
| Revenue | N/A | $589M | N/A |
No transcript is on record, and the analysis is based solely on numerical results. Therefore, management's messaging is unknown.
Bio-Rad Laboratories, Inc. is a global leader in life sciences tools and services, providing essential products for research and clinical diagnostics. As a key player in the health care sector, Bio-Rad's innovations support advancements in scientific research and medical testing, making it an important company in the ongoing growth of the life sciences industry.
Last quarter
In the last quarter, Bio-Rad reported an EPS of $2.51, slightly missing analyst expectations. The stock reacted negatively, reflecting investor concerns about growth.
EPS beat streak
1Q
EPS beat rate
50%
Avg EPS surprise
+10.95%
Avg 1-day reaction
-1.18%
Analysts expect Bio-Rad to report earnings of $1.99 per share and revenue of $589 million for Q1-2026. The market is cautious due to recent earnings misses.
Bull case
If Bio-Rad can exceed EPS expectations and show strong revenue growth, it could signal a rebound in demand for its products, boosting investor confidence.
Bear case
Conversely, if the company fails to meet expectations again, it may raise concerns about its growth trajectory and lead to further stock declines.
Key metrics to watch
Earnings Per Share (EPS)
$1.99EPS is a critical measure of a company's profitability and is closely watched by investors.
Revenue
$589MRevenue indicates the overall sales performance and market demand for Bio-Rad's products.
The print will turn on these.
Q1
Will Bio-Rad's EPS exceed the consensus estimate of $1.99?
A beat on EPS could indicate a recovery in profitability and improve investor sentiment.
Q2
What revenue growth can Bio-Rad report against the consensus of $589 million?
Revenue performance is crucial to assess the company's market position and demand for its products.
—
Est. EPS
$1.17
Est. Rev
$767M
Impl. Move
±7.6%
Why consensus could be wrong
The Street may be underestimating Bio-Rad's ability to rebound from recent performance issues, as historical data shows a strong recovery potential.
Supporting evidence
Bio-Rad has a history of surprising on the upside, with a 63% EPS beat rate over the last eight quarters.
The options market is pricing in a significant move, indicating that investors expect volatility and potential upside.
Recent insider activity, while routine, suggests confidence in the company's long-term prospects.
Key risk
If revenue growth exceeds $600 million, it could significantly alter the market's perception of Bio-Rad's recovery potential.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it follows a series of earnings misses, and investors are looking for signs of improvement.
Bull confirmed if
An EPS of $2.10 or higher would confirm a strong recovery in profitability.
Bear confirmed if
An EPS below $1.90 would suggest ongoing challenges and could lead to further declines.
What the market is pricing for the move.
Implied Move
±12.2%
Historical Avg
±1.6%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.
Options are pricing ±12.2% while BIO has averaged ±1.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
32.5%
Smart-money positioning from the most recent 13F filings.
Institutional
91.55%
of float
Insider
16.41%
of float
Holders
529
institutions
Top Holders· as of Jun 2026
First Eagle Investment Management, LLC
2,606,219 sh · $958.9M
12.02%
0.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Bio-Rad beats expectations, history suggests the stock could see a positive reaction, potentially around +1.54% on the first day.
In line / cautious
An in-line report may lead to muted reactions, as investors weigh management's commentary against recent performance.
Miss
If the company misses expectations, history suggests a potential decline of around -1.89% on the first day.
The lines on the call that would change the story.
Blackrock Inc.
1,698,929 sh · $625.1M
7.84%
1.1%
Dimensional Fund Advisors LP
944,548 sh · $347.5M
4.36%
-13.3%
Vanguard Capital Management LLC
826,972 sh · $304.3M
3.81%
-0.5%
Vanguard Portfolio Management LLC
816,198 sh · $300.3M
3.77%
-1.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.